Abstract library

8 results for "Walker".
#130 Lanreotide Autogel for malignant carcinoid syndrome: an 8-year experience
Introduction: Somatostatin analogues provide symptomatic relief in carcinoid syndrome and recently have been shown to inhibit tumor growth in metastatic gastroenteropancreatic neuroendocrine tumors (NETs). Lanreotide compounds are reported to have similar efficacy to Octreotide compounds. There is limited long-term data available on Lanreoitde Autogel.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Mohid S Khan
#503 Long-Term Stable Disease with Everolimus in a Patient with Advanced Pancreatic Neuroendocrine Tumor Enrolled in RADIANT-1
Introduction: The phase II open-label RADIANT-1 study evaluated the safety and efficacy of Everolimus (E, 10 mg/d) ± octreotide LAR (O) in patients (pts) with advanced pancreatic neuroendocrine tumors (pNET) after chemotherapy failure. Objective tumor response was 9.6% in the E group and 4.4% in the E+O group (all partial), and stable disease (SD) was 68% and 80%.
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Jenny Falkerby
#1072 Predictive Factors for Antiproliferative Activity of Octreotide LAR in Advanced Neuroendocrine Tumors
Introduction: The antiproliferative activity of Octreotide LAR in Neuroendocrine Tumors(NETs) has been demonstrated by small retrospective studies and confirmed by a prospective phase III trial(PROMID).However,there are limited data about the duration and predictors of response.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: Faidon Laskaratos
Keywords: octreotide LAR, NETs
#1126 Long-Term Follow-Up and Survival Data in Progressing Advanced Midgut Neuroendocrine Tumors Following Peptide Receptor Radionuclide Therapy
Introduction: Peptide Receptor Radionuclide Therapy (PRRT) is an effective treatment option for advanced Neuroendocrine Tumours (NET), however long term survival data is lacking.
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Mehmet Yalchin
Keywords: PRRT, PFS, OS
#1135 The Role of External Beam Radiotherapy in the Management of Advanced Neuroendocrine Tumors
Introduction: Palliative external beam radiotherapy (EBRT) is routinely used to control symptoms and disease progression in metastatic malignancies, but there is limited data in metastatic neuroendocrine tumours (NET).
Conference: 12th Annual ENETS Conference (2015)
Category: Medical treatment - Others
Presenting Author: Dr Mehmet Yalchin
Keywords: EBRT, NET
#1744 Predictors of Survival in Patients with Small Intestinal Neuroendocrine Tumours (SINETs) Associated with Mesenteric Desmoplasia
Introduction: SINETs represent 30-50% of small bowel neoplasms with a rising incidence and can be associated with mesenteric fibrosis (MF)
Conference: 14th Annual ENETS conference (2017)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Faidon M Laskaratos
Keywords: SINETs
#1799 Pilot Electronic Survey to Locate Nurses Caring for NET Patients in Europe.
Introduction: There is an assumed variance in the roles nurses have in looking after NET patients, and the different levels of knowledge.
Conference: 14th Annual ENETS conference (2017)
Category: ...none of the above
Presenting Author: Philippa Davies
#2032 Current Educational Strategies Used by Nurses Caring for NET Patients: Electronic Survey across 25 Countries
Introduction: The ENETS Nurse Group performed a short pilot survey in 2015 to locate nurses who take care of NET patients and to explore NET nurse education needs. The results of this survey were used to design a more detailed electronic survey.
Conference: 15th Annual ENETS conference (2018)
Category: Epidemiology/Natural history/Prognosis- Registries, nationwide and regional surveys
Presenting Author: Philippa Davies